Condition
Pulmonary Exacerbation
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 4 (1)
Trial Status
Recruiting1
Completed1
Terminated1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06926881Not ApplicableRecruiting
OLE Therapy With BE Patients in Home Care Study
NCT00727285Completed
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
NCT01149005Not ApplicableUnknown
Cystic Fibrosis (CF) Exacerbation and Insulin Treatment
NCT00333385Phase 4Terminated
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Showing all 4 trials